ODM 207

Drug Profile

ODM 207

Alternative Names: ODM-207

Latest Information Update: 01 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Orion
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Nov 2016 Phase-I/II clinical trials in Solid tumours (In adults, In the elderly) in Spain (PO)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 24 Jun 2014 Aurigene Discovery Technologies enters into an option and research and collaboration agreement with Orion for the development of BET bromodomain inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top